Search Results - "Lormeau, J C"

Synthesis of thrombin-inhibiting heparin mimetics without side effects by Herbert, Jean-Marc, Petitou, Maurice, Hérault, Jean-Pascal, Bernat, André, Driguez, Pierre-Alexandre, Duchaussoy, Philippe, Lormeau, Jean-Claude

“…Unwanted side effects of pharmacologically active compounds can usually be eliminated by structural modifications. But the complex heterogeneous structure of…”
Get full text

Contribution of erythrocytes to thrombin generation in whole blood by Peyrou, V, Lormeau, J C, Hérault, J P, Gaich, C, Pfliegger, A M, Herbert, J M

“…Thrombin generation (TG) initiated by diluted tissue-factor was investigated in whole human blood, in platelet-rich plasma (PRP), in platelet-poor plasma…”
Get more information

The effect of the synthetic pentasaccharide SR 90107/ORG 31540 on thrombin generation ex vivo is uniquely due to ATIII-mediated neutralization of factor Xa by Lormeau, J C, Herault, J P

“…The inhibition of thrombin generation (TG) was studied in plasma from human volunteers after single subcutaneous administrations of 4000, 8000 or 12,000…”
Get more information

DX 9065A a novel, synthetic, selective and orally active inhibitor of factor Xa: in vitro and in vivo studies by Herbert, J M, Bernat, A, Dol, F, Hérault, J P, Crépon, B, Lormeau, J C

“…DX 9065A is the first member of a newly developed series of synthetic and selective inhibitors of factor Xa. DX 9065A inhibited in a dose-dependent manner…”
Get more information

Comparative effects of two direct and indirect factor Xa inhibitors on free and clot-bound prothrombinase by Hérault, J P, Bernat, A, Pflieger, A M, Lormeau, J C, Herbert, J M

“…Factor Xa, as with thrombin, binds to the clot and contributes to the propensity of thrombi to activate the coagulation system. The aim of this work was to…”
Get more information

Absence of cross-reactivity of SR90107A/ORG31540 pentasaccharide with antibodies to heparin-PF4 complexes developed in heparin-induced thrombocytopenia by Amiral, J, Lormeau, J C, Marfaing-Koka, A, Vissac, A M, Wolf, M, Boyer-Neumann, C, Tardy, B, Herbert, J M, Meyer, D

“…New carbohydrate-based anticoagulants devoid of the side effects of unfractionated heparin are currently under development and show a major potential for…”
Get more information

Biochemical and Pharmacological Properties of SANORG 32701: Comparison With the `Synthetic Pentasaccharide' (SR 90107/ORG 31540) and Standard Heparin by Herbert, J.M, Herault, J.P, Bernat, A, van Amsterdam, R.G.M, Vogel, G.M.T, Lormeau, J.C, Petitou, M, Meuleman, D.G

“…SANORG 32701 is a new sulfated pentasaccharide obtained by total chemical synthesis. It is an analogue of the ``synthetic pentasaccharide'' (SR 90107/ORG…”
Get full text

Molecular profiling and weight determination of heparins and depolymerized heparins by Ahsan, A, Jeske, W, Hoppensteadt, D, Lormeau, J C, Wolf, H, Fareed, J

“…The recently proposed calibrant LHN-1 (lot F537; henceforth designated F537), for the molecular weight (MW) determination by high-performance size-exclusion…”
Get more information

Heparin reverses the procoagulant properties of stimulated endothelial cells by Cadroy, Y, Gaspin, D, Dupouy, D, Lormeau, J C, Boneu, B, Sié, P

“…We examined the ability of unfractionated heparin to modulate the procoagulant activities of stimulated endothelial cells (EC). Confluent human venous…”
Get more information

Chemical synthesis of glycosaminoglycans : new approaches to antithrombotic drugs by PETITOU, M, LORMEAU, J.-C, CHOAY, J

“…Sanofi, Elf Aquitaine's pharmaceutical subsidiary, is a world leader in the manufacturing of antithrombotic drugs. The development of Heparin-based…”
Get full text

Synthesis and Pharmacological Properties of a Close Analogue of an Antithrombotic Pentasaccharide (SR 90107A/ORG 31540) by Petitou, Maurice, Duchaussoy, Philippe, Jaurand, Guy, Gourvenec, Françoise, Lederman, Isidore, Strassel, Jean-Marc, Bârzu, Tereza, Crépon, Bertrand, Hérault, Jean-Pascal, Lormeau, Jean-Claude, Bernat, André, Herbert, Jean-Marc

“…The synthetic pentasaccharide (1) corresponding to the heparin sequence which binds to, and activates, antithrombin III (AT III) is a potent antithrombotic…”
Get full text

Structural determinants of heparin's growth inhibitory activity. Interdependence of oligosaccharide size and charge by T C Wright, Jr, J J Castellot, Jr, M Petitou, J C Lormeau, J Choay, M J Karnovsky

“…The glycosaminoglycan heparin inhibits the growth of several cell types in vitro including smooth muscle cells and rat cervical epithelial cells. The…”
Get full text

New synthetic heparin mimetics able to inhibit thrombin and factor Xa by Petitou, Maurice, Duchaussoy, Philippe, Driguez, Pierre-A., Hérault, Jean-P., Lormeau, Jean-C., Herbert, Jean-M.

“…Synthetic pentadeca-, heptadeca- and nonadecasaccharides, comprising an antithrombin III (AT III) binding pentasaccharide prolonged at the non-reducing end by…”
Get full text

Comparative inhibition of extrinsic and intrinsic thrombin generation by standard heparin, a low molecular weight heparin and the synthetic ATIII-binding pentasaccharide by Lormeau, J C, Herault, J P

“…The inhibiting effect of standard heparin, CY216 and the ATIII-binding synthetic pentasaccharide on extrinsic and intrinsic thrombin generation were quantified…”
Get more information

Antiproliferative effects of novel, nonanticoagulant heparin derivatives on vascular smooth muscle cells in vitro and in vivo by Pukac, LA, Hirsch, GM, Lormeau, JC, Petitou, M, Choay, J, Karnovsky, MJ

“…The proliferation of vascular smooth muscle cells (VSMC) is strongly inhibited by whole heparin both in vitro and in vivo. To identify and characterize…”
Get full text

Preparation and anti-HIV activity of O-acylated heparin and dermatan sulfate derivatives with low anticoagulant effect by Barzu, Tereza, Level, Michel, Petitou, Maurice, Lormeau, Jean Claude, Choay, Jean, Schols, Dominique, Baba, Masanori, Pauwels, Rudi, Witvrouw, Myriam, De Clercq, Erik

“…In order to increase the ratio of anti-HIV activity to anticoagulant activity, glycosaminoglycan derivatives selectively substituted at OH and/or COOH groups…”
Get full text

Structural Determinants of the Capacity of Heparin to Inhibit the Proliferation of Vascular Smooth Muscle Cells. II. Evidence for a Pentasaccharide Sequence That Contains a 3-O-Sulfate Group by Castellot, John J., Choay, Jean, Lormeau, Jean-Claude, Petitou, Maurice, Sache, Edgar, Karnovsky, Morris J.

“…Earlier work from our laboratory demonstrated that heparin inhibited the proliferation of vascular smooth muscle cells in vivo and in vitro. Both anticoagulant…”
Get full text

The mode of action of CY216 and CY222 in plasma by Béguin, S, Wielders, S, Lormeau, J C, Hemker, H C

“…Three fractions of the low molecular weight heparin CY216 (fraxiparin, mean molecular weight [MMW] 5,090), with MMWs of respectively, 3,090, 4,400 and 7,910…”
Get more information

Contribution of monosaccharide residues in heparin binding to antithrombin III by Atha, Donald H, Lormeau, Jean Claude, Petitou, Maurice, Rosenberg, Robert D, Choay, Jean

“…The importance of 3-O- and 6-O-sulfated glucosamine residues within the heparin octasaccharide iduronic acid(1)---N-acetylglucosamine…”
Get full text

Heparin and low molecular weight heparins inhibit prothrombinase formation but not its activity in plasma by Ofosu, F A, Lormeau, J C, Craven, S, Dewar, L, Anvari, N

“…Factor V activation is a critical step preceding prothrombinase formation. This study determined the contributions of factor Xa and thrombin, which activate…”
Get more information